Continuing Medical Education Information

Target Audience

This program is intended for endocrinologists who specialize in nutrition and obesity. It is also intended for primary care physicians and other members of the endocrine care team.

Learning Objectives

By the end of the meeting, participants will be able to:

  • Describe the linkages between obesity and its associated comorbidities
  • Identify patient treatment options for obesity management
  • Apply best practices in the assessment and treatment of obesity to reduce negative health outcomes from comorbidities
  • Address the issue of weight bias in clinical practice
  • Discuss the role of nutrition in prevention of obesity
  • Characterize health disparities and social determinant of health in management of obesity

Accreditation and Designation Statements


The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this Live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

New Terms: 
  • Standards for Integrity and Independence in Accredited Continuing Education- replaced “Standards for Commercial Support”.

  • Released in December 2020 to replace Standards for Commercial Support: Standards to Ensure Independence in CME Activities.

  • Mitigate- replaced “resolve”. 

  • The term mitigate replaces resolve, in guidance related to relevant financial relationships, to clarify that accredited providers are expected to mitigate the potential effect of these relationships on accredited continuing education. The expectation hasn’t changed, only the term used to describe it.

  • Accredited continuing education-replaced “continuing medical education”.

  • The term accredited continuing education replaces continuing medical education to be inclusive of all health professions. We include accredited to explicitly differentiate between accredited and nonaccredited education providers and education.

  • Ineligible companies-replaced ‘commercial interests”.

  • These organizations were referred to as commercial interests in the Standards for Commercial Support. The new term is intended to clarify that eligibility for accreditation is not based on whether an organization is for-profit or nonprofit but is based on its primary mission and function.

  • Eligible organizations: Organizations that are eligible to be accredited in the ACCME System.

  • Evidenced-based medicine.

  • In the past we used “Evidenced-based education, which meant that topics had followed a scientific approach to determining it’s widely accepted practice.  Can still use that term but we can also note that accredited continuing education is an appropriate place to discuss, debate and explore new and evolving topics, these areas need to be clearly identified as such within the program and individual presentations. It is the responsibility of accredited providers to facilitate engagement with these topics without advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning.

  • i.e.  Can teach about but cannot discuss “How To” in controversial topics (IE COVID-19 treatments).

  • i.e.  Can’t make recommendations for non-evidenced based content.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.
Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared with the American Board of Internal Medicine (ABIM) through the Accreditation Council for Continuing Medical Education (ACCME) Program and Activity Reporting System (PARS).

Applicants for certification through the American Board of Obesity Medicine (ABOM) may claim up to 13.75 Group Two CME credits toward the ABOM requirement when providing a CME certificate or transcript from this course. Learn more about obesity medicine certification at

PIM logo

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and AACE. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 13.75 contact hours.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 13.75 contact hours.

Disclosure and Conflicts of Interest Policy:

American Association of Clinical Endocrinology (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

Planning Committee

  • Karl Nadolsky, DO, FACE (Chair)
  • Monica Agarwal, MD, FACE, MEHP (Vice-Chair)
  • Bartolo Burguera, MD, PhD
  • Thanh Hoang, DO, FACE
  • Lakshmi Kannan, MD
  • Reshmi Srinath, MD

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.


Name Conflict Type Name of Ineligible Company
Brandi Addison, MD Consulting fees Novo Nordisk
Diana Isaacs, PharmD, BCPS, BCACP,
Consulting fees
Abbott, Dexcom
Insulet, Novo Nordisk
Scott Isaacs, MD Consulting fees Madrigal, Medplace, Quest
Samantha R. Harris, MD Consulting fees
Research grant
Sanofi, Zealand Pharma
Eli Lilly
Ania Jastreboff, MD Consulting fees,
Grant/research support
Intelihealth, Novo Nordisk, Pfizer, Scholar Rock, Rhythm Pharmaceuticals
Rahul Pannala, MD Grant research
Consulting fees
Fractyl Laboratories
HCL Technologies, Nestle Health Sciences
Rachel Pessah-Pollack, MD, FACE Consulting fees Boehringer Ingelheim/Eli Lilly, Health Monitor

The remaining faculty for this educational activity has no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Commercial Support

This activity is supported by educational grants from:

  • Novo Nordisk Inc.
  • Rhythm Pharmaceuticals